Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$10.89 USD
+0.07 (0.65%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $10.87 -0.02 (-0.18%) 5:14 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AVXL 10.89 +0.07(0.65%)
Will AVXL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AVXL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVXL
Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
AVXL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Beat the Market the Zacks Way: Amgen, DRDGOLD, Anavex in Focus
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why
Best Momentum Stocks to Buy for January 21st
Other News for AVXL
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August ...
Anavex Life Sciences (AVXL) Maintains 'Buy' Rating with $46 Target | AVXL Stock News
Anavex (AVXL) Reveals Promising Data for Alzheimer's Treatment
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral ...
Anavex announces precision medicine results of oral blarcamesine treatment